GYRE THERAPEUTICS, INC. — Form 8-K
Filed August 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Gyre Therapeutics presented an August 2026 investor deck outlining its strategy as a dual-engine company: a China-based commercial platform generating revenue from ETUARYTM (pirfenidone for IPF, FY26 guidance $100.5–$111M) and F351 (hydronidone for CHB-induced liver fibrosis, NDA accepted by China NMPA May 2026, potential launch early 2027), plus a U.S.-directed R&D engine advancing targeted protein degraders (TPDs) and degrader-antibody conjugates (DACs). Key pipeline assets include CG923308 (CDK2/Cyclin E dual degrader for CDK4/6i-resistant breast cancer, IND submission Q1'27), CG620953 (TYK2/JAK1 degrader for SLE/RA, IND submission Q1'27), CG009301 (GSPT1 degrader in Phase 1 for AML/MDS/ALL, Phase 1 data expected at trial completion), and CG001419 (TRK degrader for cancer-induced bone pain, Phase 1 completed, Phase 2 planning).
Why this rating
Presentation-only disclosure; no material transaction, deal, or financial event. Pipeline timeline and commercial guidance are forward-looking and speculative. Routine investor communications relative to $72.6M market cap.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.